Chimeric Therapeutics Statistics
Total Valuation
ASX:CHM has a market cap or net worth of AUD 8.06 million. The enterprise value is 2.99 million.
Market Cap | 8.06M |
Enterprise Value | 2.99M |
Important Dates
The last earnings date was Thursday, May 29, 2025.
Earnings Date | May 29, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
ASX:CHM has 2.02 billion shares outstanding. The number of shares has increased by 84.50% in one year.
Current Share Class | 2.02B |
Shares Outstanding | 2.02B |
Shares Change (YoY) | +84.50% |
Shares Change (QoQ) | +20.56% |
Owned by Insiders (%) | 16.37% |
Owned by Institutions (%) | 1.95% |
Float | 1.67B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.95 |
PB Ratio | 1.36 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.17 |
EV / Sales | 1.47 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.70
Current Ratio | 0.70 |
Quick Ratio | 0.69 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -206.87 |
Financial Efficiency
Return on equity (ROE) is -180.09% and return on invested capital (ROIC) is -111.60%.
Return on Equity (ROE) | -180.09% |
Return on Assets (ROA) | -48.71% |
Return on Invested Capital (ROIC) | -111.60% |
Return on Capital Employed (ROCE) | -209.20% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.09 |
Inventory Turnover | n/a |
Taxes
In the past 12 months, ASX:CHM has paid 220,485 in taxes.
Income Tax | 220,485 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -76.47% in the last 52 weeks. The beta is 1.51, so ASX:CHM's price volatility has been higher than the market average.
Beta (5Y) | 1.51 |
52-Week Price Change | -76.47% |
50-Day Moving Average | 0.00 |
200-Day Moving Average | 0.01 |
Relative Strength Index (RSI) | 43.08 |
Average Volume (20 Days) | 9,427,175 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ASX:CHM had revenue of AUD 2.04 million and -17.83 million in losses. Loss per share was -0.02.
Revenue | 2.04M |
Gross Profit | 2.04M |
Operating Income | -17.68M |
Pretax Income | -17.61M |
Net Income | -17.83M |
EBITDA | -16.60M |
EBIT | -17.68M |
Loss Per Share | -0.02 |
Balance Sheet
The company has 5.07 million in cash and n/a in debt, giving a net cash position of 5.07 million or 0.00 per share.
Cash & Cash Equivalents | 5.07M |
Total Debt | n/a |
Net Cash | 5.07M |
Net Cash Per Share | 0.00 |
Equity (Book Value) | 5.94M |
Book Value Per Share | 0.00 |
Working Capital | -3.07M |
Cash Flow
Operating Cash Flow | -5.51M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | 100.00% |
Operating Margin | -866.08% |
Pretax Margin | -862.74% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ASX:CHM does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -84.50% |
Shareholder Yield | n/a |
Earnings Yield | -221.22% |
FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
ASX:CHM has an Altman Z-Score of -7.58 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -7.58 |
Piotroski F-Score | 1 |